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lower tendency of bleeding and in reducing stroke incidences. This study aims to 
compare the pattern of anticoagulants used and to assess their safety and efficacy 
by evaluating bleeding and stroke occurrences in both groups. Methods: This is a 
retrospective study carried out at a hospital with hematology clinic in the state of 
Selangor, Malaysia. The samples of the study were patients with atrial fibrillation, 
prescribed with warfarin or dabigatran. Data collected includes patients’ demo-
graphics, co-morbidities, and stroke and haemorrhage events. Results: A total of 
71 patients were recruited in this study with 21, 21 and 29 patients were on Warfarin, 
Dabigatran 110 mg and Dabigatran 150 mg respectively. Out of 50 Dabigatran users, 
36 of them are warfarin-experienced. 1 out of 21 patients on warfarin experienced 
stroke while none in both 110 and 150mg dabigatran group. A total of 11 (52.4%) 
of warfarin patients experienced bleeding with 2 of them having major bleeding 
whereas, only 4 (8%) out of 50 dabigatran patients experienced minor bleeding, 
1 in patient who were on Dabigatran 150mg and 3 patients who were on Dabigatran 
110mg. ConClusions: The pattern of anticoagulant used for stroke prophylaxis 
in atrial fibrillation is slowly changing from Warfarin to Dabigatran. Evaluation of 
safety and efficacy profile of Warfarin shows that Warfarin requires more extensive 
management and monitoring in order to achieve therapeutic goals with fewer side 
effects. Comparison between both anticoagulants show that Dabigatran is safer and 
more effective compared to warfarin.
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objeCtives: In patients receiving long-term low-dose aspirin for prevention of 
adverse cardiovascular (CV) events, proton pump inhibitors (PPIs) are often prescribed 
to prevent aspirin-induced gastrointestinal bleeding. However, PPIs may reduce the 
therapeutic efficacy of aspirin. This study investigated the effect of co-administration 
of PPIs in aspirin users with a first acute myocardial infarction (AMI) or stroke on the 
risk of recurrence of such a CV event. Methods: A retrospective cohort study using 
the Clinical Practice Research Datalink (CPRD) was conducted in patients with at least 
one occurrence of AMI or stroke between 1998 and 2014, and who received at least 
one prescription of aspirin (30-325 mg/day) after the first AMI or stroke. Concomitant 
use of aspirin and PPIs was defined as overlaps between periods of current use of 
aspirin and of PPIs. The hazard ratio (HR; i.e. the instantaneous risk in concomitant 
use of aspirin and PPIs relative to that in aspirin use alone) was estimated using 
a Cox proportional hazards model with time-varying covariates. The estimate was 
adjusted for multiple potential confounders such as age, BMI, socioeconomic status, 
smoking status and history of diabetes. Results: The study population consisted of 
39,794 patients. During the follow-up period [range: 0.0-16.9 years; mean (SD): 4.1 (3.8) 
years], 18,094 patients had no prescription of PPIs, and 13,013 patients concomitantly 
used aspirin and PPIs for a cumulative duration longer than 50% of the cumulative 
duration of aspirin use. AMI or stroke recurred in 4,307 patients, with mean (SD) time 
from the first to the second event being 2.6 (2.7) years. Adjusted HR (95% CI) of AMI 
or stroke in aspirin plus PPIs versus aspirin use was 1.23 (1.07-1.41). ConClusions: 
Co-administration of PPIs in aspirin users with a first AMI or stroke is associated with 
an increased risk of recurrence of such a CV event.
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objeCtives: The management of SI in patients at high CV risk is poorly understood 
within Canada. The present study was conducted to describe SI patient characteris-
tics and their management and to estimate the incidence in the high-risk popula-
tion. Methods: We retrospectively analysed data from an open cohort of patients 
initiating statin therapy between 2004 and 2012, using the Southwestern Ontario 
primary-care practice database. Inclusion criteria were: diagnosis of dyslipidaemia, ≥ 1 
statin prescription, and ≥ 2 years of statin-free baseline data. SI index date was identi-
fied as the first occurrence of SI-related symptoms associated with a change in statin 
therapy. Patients were stratified into three CV risk levels (low, intermediate, high). 
Here, we report results for the high-risk subgroup. Results: Of 41,733 patients who 
initiated statin therapy, 14,607 were at high CV risk; 1,294 patients in this subgroup 
had SI. The mean±SD age was 61±8.9 years, 53% (n= 684) were male, and low-density 
lipoprotein cholesterol (LDL-C) was 2.8±1.1 mmol/L. Among patients identified with 
SI, 13% (n= 170) experienced myopathy and 87% (n= 1124) had SI-related symptoms. 
There were nine rhabdomyolysis cases, two resulting in hospitalization. Statins were 
discontinued in 412 (32%) patients, and 677 (52%) patients had their statin dosage 
decreased. At the SI index date 84% (n= 1085) of patients were on LDL-C target, with 
the on-target proportion decreasing to 49% (n= 638) 6 months post-SI. Among the 656 
patients off-target at 6 months post-SI, 28% (n= 185) decreased statin dose or stopped 
statins, and 46% (n= 299) were switched to a non-statin therapy. ConClusions: SI 
affects the optimal treatment of dyslipidaemia in this high-risk population. A number 
of patients do not achieve their LDL-C target and are undertreated because they do 
not tolerate their initial statin dose or have to be treated with a non-statin therapy. 
These patients are at increased CV risk.
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with and without a new CVE between 01/01/2006 and 06/30/2012. CVEs included pri-
mary inpatient claims for myocardial infarction (MI), unstable angina (UA), ischemic 
stroke (IS), transient ischemic attack, revascularization and heart failure. Patients 
were stratified into two CV risk cohorts: history of cardiovascular disease (CVD) [MI, 
UA, coronary artery bypass graft, percutaneous coronary intervention, IS] and coro-
nary heart disease risk equivalent (CHD RE) [peripheral artery disease, abdominal 
aortic aneurysm, coronary artery disease, diabetes, dyslipidemia]. Propensity score 
matching was applied to compare the burden among patients with and without a 
new CVE, ranging from 1 month through 3 years post-CVE date. ConClusions: 
High-risk hyperlipidemia patients with new CVEs had significantly higher burden of 
hospitalizations and healthcare visits compared to matched patients without new 
CVEs, evident in the 1st month and sustained through 3 years post-CVE.
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objeCtives: To compare the effectiveness and safety of oral anticoagulants (OACs) 
-NOAC and VKA- in patients with atrial fibrillation (AF) in real-world clinical prac-
tice. Methods: Retrospective population-based cohort study. All new users of OAC 
from Nov2011 to Feb2014 with AF were included (N= 21841). Data were obtained by 
linking diverse electronic databases of the Valencia Region, Spain. Incidence rates 
were estimated. Cox proportional hazards models adjusted for sociodemographic, 
clinical, healthcare use data, and propensity scores assessed the risk of several 
outcomes on effectiveness and safety of each NOAC compared with acenocumarol. 
Apixaban and warfarin patients were excluded because of few person-time obser-
vations Results: The incidence of ischemic stroke was 12.5, 8.7 and 10.8 per 1000 
person-years for acenocumarol, dabigatran and rivaroxaban. After adjustment 
no differences were found for NOAC in the risk of ischemic stroke compared to 
acenocumarol (HR:0.78, 95%CI:0.51-1.20 for dabigatran; HR:0.76, 95%CI:0.42-1.35 
for rivaroxaban). Regarding the incidence of mortality (80.2, 65.1 and 91.7, respec-
tively) no increased risk was found (HR:0.96, 95%CI:0.81-1.12 for dabigatran; HR: 1.16, 
95%CI:0.95-1.42 for rivaroxaban). The incidence of gastrointestinal bleeding was 18.3, 
21.4 and 14.4, respectively, being dabigatran associated with a higher risk (HR:1.44, 
95%CI:1.08-1.92) but not rivaroxaban (HR: 0.72, 95%CI: 0.43-1.19). However, no dif-
ferences were found for major gastrointestinal bleeding (HR: 1.01, 95%CI: 0.59-1.73 
for dabigatran; HR:0.43, 95%CI:0.16-1.17 for rivaroxaban). Regarding the incidence 
of intracranial haemorrhage (8.8, 3.0 and 5.4, respectively), dabigatran was found to 
be associated with a decreased risk (HR:0.36, 95%CI:0.18-0.74), and no differences 
for rivaroxaban (HR: 0.56, 95%CI 0.25-1.27). ConClusions: NOAC were not associ-
ated with an increased risk of stroke or death compared with acenocumarol among 
newly treated patients with AF. Dabigatran was associated with lower risk of intrac-
ranial haemorrhage and higher risk of gastrointestinal bleeding. The risk of major 
gastrointestinal bleeding related to NOAC was similar to that for acenocumarol.
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objeCtives: Warfarin is an oral anticoagulant prescribed as prophylaxis for patients 
with high risk of developing thrombosis, pulmonary embolism as well as treatment 
for recurrent and idiopathic incident of pulmonary embolism. This study aims to 
compare time in therapeutic range (TTR) of warfarin in patients with pulmonary 
embolism with bleeding and stroke and determine reasons of INR falling out of 
range. Methods: This is a retrospective study carried out at a tertiary-care hospital 
with anticoagulation clinic in the state of Selangor, Malaysia. The samples of the 
study were patients with pulmonary embolism, prescribed with warfarin from year 
2009 to 2014. The data collected includes patients’ demographics, co-morbidities, 
and international normalized ratio (INR). TTR was determined using Rosendaal 
method. Patients’ stroke, haemorrhage events and reasons of INR being outside the 
range were recorded. Results: TTR of 20 out of 30 patients (66.67%) were found to 
be outside the range (< 75%) with 8 of them (40%) experiencing bleeding. The remain-
ing 10 patients (33.33%) recorded TTR of more than 75%, where 3 of them (30%) 
experienced bleeding during their warfarin treatment. Out of the total 11 patients 
who bled, 10 of them had minor bleeding. The other 1 patient from TTR < 75% group 
had major bleeding. None of the patients from both groups experienced stroke. The 
highest identified reason of International Normalized Range (INR) being outside 
the range was found to be drug-drug interactions, which were seen in 9 patients 
(30%). ConClusions: Warfarin treatment should be maintained within the tar-
geted INR range to avoid unwanted events such as bleeding and stroke. Based on the 
findings of this study, it can be concluded that warfarin monitoring should be done 
continuously and thoroughly to ensure that INR level falls within the targeted range.
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objeCtives: Warfarin has been used for more than 50 years as stroke prophylaxis 
in patients with atrial fibrillation. New oral anticoagulant, Dabigatran, was devel-
oped and shown to be safer and more efficacious compared to Warfarin due to its 
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tion occurred among 36% and 50% of P-PGI2 and NP-PGI2 patients, respectively; mean 
(SD) weeks to augmentation were 7 (15) and 3 (8). ConClusions: Use of other PAH 
therapies prior to PGI2 is common, particularly among NP-PGI2. Our findings suggest 
that parenteral PGI2 may be reserved for more severe PAH patients.
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objeCtives: The long-term use of ß-blockers has been shown to improve the out-
comes of patients with heart failure (HF). However, it is still disputed whether this 
is a class effect, and, specifically, whether carvedilol or bisoprolol are superior to 
metoprolol tartrate. The objective of this study is to compare the effectiveness of 
ß-blockers for patients with HF in a clinical practice. Methods: We conducted an 
observational cohort study using the Quebec administrative databases to identify 
patients with HF who were prescribed a ß-blocker after the diagnosis of HF e.g. 
metoprolol tartrate, carvedilol or bisoprolol. We used descriptive statistics to charac-
terize the patients by the type of ß-blocker prescribed at discharge. The unadjusted 
mortality for users of each ß-blocker was calculated using Kaplan-Meier curves and 
compared using the log-rank test. To account for differences in follow-up and to 
control for differences among patient characteristics, a multivariate Cox propor-
tional hazards model was used to compare the all-cause mortality, cardiovascular 
mortality and HF readmission. We run also analysis by matching with a propensity 
score. Results: Of the 3,732 patients with HF, with a median follow-up of 3.1 years 
per patient, the crude annual incidence of death was 16.5% with metoprolol tartrate, 
15.8% with carvedilol, and 17.5% with bisoprolol. After controlling for several dif-
ferent covariates, we found that carvedilol (hazard ratio [HR] 0.95, 95% confidence 
interval [CI] 0.82-1.10) and bisoprolol (HR 1.06, 95% CI 0.95-1.18) were not superior to 
metoprolol tartrate in improving survival. Similar results were observed for cardio-
vascular mortality. But, HF readmission rate was significantly increased from 20 to 
26% with carvedilol and bisoprolol compare to metoprolol tartrate. ConClusions: 
Based on observational study, we suggest that there is no evidence of a class effect 
for β -blockers in older patients with HF on mortality, but the choice of β-blocker may 
have impact on the rate of HF readmission.
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objeCtives: Dyslipidaemia is an important and well recognised modifiable CV 
risk factor. This study was undertaken to determine the proportion of patients 
reaching and maintaining the low-density lipoprotein cholesterol (LDL-C) target in 
a large Canadian cohort and the prevalence of CV risk factors. Methods: We ret-
rospectively analysed data from an open cohort of patients initiating statin therapy 
between 2004 and 2012, using the Southwestern Ontario primary care practice data-
base. Inclusion criteria were: ≥ 2 years statin-free, diagnosis of dyslipidaemia, and ≥ 1 
statin prescription. Patients were stratified into three CV risk levels (low, intermedi-
ate, high); results are reported for the high-risk subgroup. CV risk factors and preva-
lence were estimated using 2012 data. Results: Of 41,733 patients who initiated 
statin therapy, 14,607 (35%) were at high CV risk. At baseline, the mean±SD age was 
54±7 years, 51% were male, and LDL-C was 3.07±0.41 mmol/L. In 2012, there were 
13,985 high-risk patients, with a mean±SD of 3±2 CV risk factors. The most frequent 
CV risk factors were: age (females > 55 years + males > 45 years: 91%, n= 12,727), 
obesity (body mass index > 27 kg/m2: 36%, n= 5,035), high-risk hypertension (31%, 
n= 4,395), history of CV disease (17%, n= 2,377), and diabetes (14%, n= 1,958). Among 
high-risk patients in 2012, 1,390 (10%) received no statins, of whom 1,266 (91%) had 
statin intolerance (SI) and only 17 (< 1%) received no lipid-lowering agent. Across 
2004–2012, patients took 6.7±2.2 months to reach the LDL-C target. After 1 year of 
statin treatment, 25% (n= 3,652) had not reached the target; this proportion remained 
stable over time. Among the 1,294 patients with SI, 84% were on target at SI diag-
nosis and only 49% were still on target 6 months post-SI. ConClusions: Despite 
widespread statin use, dyslipidaemia represents a significant burden for high-risk 
patients. Many patients do not achieve their LDL-C goals with statin therapy.
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objeCtives: Estimate annual utilization and cost of prostacyclins (PGI2) among 
patients with pulmonary arterial hypertension (PAH). Methods: Truven® 
Commercial and Medicare Databases were used to identify annual cohorts of adults 
with PAH (i.e., International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) diagnosis codes [416.0 or 416.8] and ≥ 1 claims for PAH-
specific medications) between calendar-year (CY) 2010 and CY2014. Patients with 
≥ 1 claims for PGI2 were deemed PGI2 users. PGI2 use was categorized as parenteral 
vs. non-parenteral. PAH-related included costs of PAH-specific medications and all 
medical claims with a relevant diagnosis code. Results: A total of 12,306 patients 
met selection criteria for at least 1 CY of the study period. Annual prevalence of 
PGI2 use ranged from 20% to 22%. Among PGI2 users, treprostinil use increased 
from 50% in CY2010 to 71% in CY2014; corresponding decreases for epoprostenol 
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objeCtives: To assess, in a community setting, the clinical and economic outcomes 
of hypercholesterolemic patients with ACS and diabetes treated with statins over 
a one-year follow-up. Methods: Data for over 2.9 million subjects were extracted 
from 6 Local Health Units (ARNO Observatory, an administrative database contain-
ing data on hospitalizations, prescriptions and diagnostic/outpatient visits). The 
index period lasted from January 1 to December 31, 2011. Patients with ACS and dia-
betes were followed-up from the index hospitalization in 2011 for a period of 1 year. 
The rate of prescription, dosage, adherence to statin treatment and related health 
care costs were evaluated. Results: Of 2,989,512 subjects identified, 6,226 patients 
(0.2%) were hospitalized for ACS: 86.4% were aged over 60 years. Hospital death rate 
was 4.1%. Among ACS cases, 1,917 had diabetes (30.8%). At 1-year follow-up, 85.3% 
of patients with ACS and diabetes, were prescribed statin therapy with 84.9% being 
prescribed high intensity statins (Atorvastatin 40, 80 mg/dL, Rosuvastatin 20, 40 mg/
dL). Adherence to treatment (attributed to all patients who received the correct daily 
dosage during the one year follow-up period with a 20% tolerability – CORE Study 
2013) was higher among high intensity statins users compared to lower intensity 
statins users (67.1% vs 38.9%). Over the 1-year follow-up period, 69.3% of ACS dia-
betic patients were re-hospitalized, of which 55.6% were hospitalized for cardiovas-
cular events. The average yearly cost per patient supported by NHS was 16,897€ /year: 
14,199€ for hospitalizations; 1,691€ for drugs; 1,008€ for diagnostic and outpatient 
visits. ConClusions: Patients with ACS and diabetes have high direct healthcare 
costs, with re-hospitalization being the main cost driver. Adherence to statin treat-
ment was sub optimal. Local Health Authorities together with Cardiologists and 
GPs are working to bridge the gap between evidence-based recommendations and 
clinical practice in order to contain morbidity and health costs.
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objeCtives: Previously, we reported lipid modifying therapy (LMT) and low-density 
lipoprotein cholesterol (LDL-C) goal attainment among patients at high-risk for 
cardiovascular events. The objective of the current study was to describe clinical 
characteristics, lipid modifying therapy (LMT) treatment, and LDL-C attainment of 
a familial hypercholesterolemia (FH) cohort. Methods: For this cross-sectional 
study, the PHARMO Database Network was used. Patients aged ≥ 18 years with an 
LDL-C measurement in 2012 (index date) and ≥ 2 years of continuous enrollment 
in the pre-index period were considered. We identified FH patients by searching 
for a diagnosis of FH recorded by a general practitioner (GP) in the 2-year pre-index 
period or by application of the Dutch Lipid Clinic Network (DLCN) criteria (score 
≥ 6). Patients with a filled prescription for LMT within 45 days of index were con-
sidered to be taking the medication. LDL-C goal of ≤ 100mg/dL was considered at 
goal. Results: 1,132 patients were identified, with 92% having a recorded FH diag-
nosis by a GP. Mean (±SD) age was 57 (±14) years and 43% were male. Approximately 
33% had co-morbid diabetes, 42% had hypertension and the mean (±SD) LDL-C was 
138 (±58) mg/dL In total, 54% were currently treated with LMT; 13% high-intensity 
statin (atorvastatin 40/80mg, rosuvastatin 20/40mg, simvastatin 80mg); 39% mod-
erate-to low-intensity statin and 2% other non-statin LMT. LDL-C ≥ 100 mg/dl was 
observed in 77% of the patients and 27% had an LDL-C ≥ 160mg/dL. Among the 47% 
not currently treated with LMT, 89% had an LDL-C level ≥ 100 mg/dl and 74% had no 
evidence of any LMT in the pre-index period. ConClusions: These data suggest 
that FH patients in the Netherlands are undertreated by GPs and not at goal. This 
underscores the need for improving treatment rates with LMT and benefit of add-on 
treatment options in those not able to achieve goals on current LMTs.
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demogrAPhiCs, CliniCAl ChArACteristiCs, And treAtment PAtterns 
of PAtients newly stArted on ProstACyClin therAPy for PulmonAry 
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objeCtives: Describe demographics, clinical characteristics and treatment patterns 
(i.e., discontinuation, switching, or augmentation) of patients with pulmonary arterial 
hypertension (PAH) initiating prostacyclin (PGI2) therapy. Methods: Using Truven® 
Commercial and Medicare Databases (2010–2014), two non-mutually exclusive cohorts 
were constituted. The first consisted of initiators of parenteral PGI2 (P-PGI2); the sec-
ond, non-parenteral PGI2 (NP-PGI2). All patients were required to have evidence of 
PAH (i.e., ≥ 1 claims with a PAH diagnosis or ≥ 1 pharmacy claims for PAH-specific 
medications). Demographics and clinical characteristics were assessed during the 
three months prior to PGI2 initiation. Treatment patterns were assessed until switch/
discontinuation, or end of follow-up. Results: Of the 12,306 PAH patients identified 
during the study period, 1,569 (12.7%) were new initiators of PGI2 (755 [6.1%] for P-PGI2 
and 1,003 [8.2%] for NP-PGI2). Approximately 70% of each cohort was female. P-PGI2 
patients were nominally younger than NP-PGI2 patients (54.2 vs. 59.4 years), yet, had 
more comorbidities, hospitalizations, emergency room visits and mean (standard 
deviation [SD]) PAH-related medical costs than NP-PGI2 patients ($46,038 [$72,208] 
vs. $28,210 [$58,386]) during the three months before PGI2 initiation. P-PGI2 patients 
had less other PAH medication use than NP-PGI2 patients prior to PGI2 initiation (43% 
vs. 67%). Twenty-seven percent and 19% of P-PGI2 and NP-PGI2 patients, respectively, 
discontinued initial PGI2; mean (SD) weeks to discontinuation was 22 (35) and 20 (23). 
Only 7% of P-PGI2 and 11% of NP-PGI2 patients switched; mean (SD) weeks to switch 
was approximately 8 (12.5) in both groups. Augmentation with another PAH medica-
